Nucana (N040) AI Stock Analysis

Nucana

(Frankfurt:N040)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strengthened oncology IPThe European composition-of-matter patent strengthens protection for NUC-7738 across a major market and adds to NuCana’s broad issued-patent estate. Durable intellectual property can support clinical investment, preserve differentiation, and improve potential commercialization prospects if development succeeds.

Negative Factors

No revenue generationNuCana remains pre-revenue, so its business has not yet demonstrated commercial demand or an operating revenue engine. Continued dependence on clinical development means future value remains tied to successful trials and eventual product approval rather than established sales.

Nucana (N040) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.13M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.3
Beta (1Y): -1.75
Revenue Growth: ―
EPS Growth: 99.54%
Country: Germany
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Nucana Business Overview & Revenue Model

Company Description

NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is pro...

Nucana Risk Analysis

Nucana disclosed 92 risk factors in its most recent earnings report. Nucana reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.Q4, 2023

2.Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer cybersecurity incidents, which could result in a material disruption of our product development programs, and could subject us to liability.Q4, 2023

3.Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.Q4, 2023

Nucana Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:N040 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMRN	52Neutral	$9.08M	-3.10	-31.88%	―	10.41%	42.44%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APRE	50Neutral	$6.10M	-0.45	-46.72%	―	-99.38%	53.42%
XBIO	42Neutral	$4.80M	-1.72	-40.62%	―	33.30%	40.59%

* Healthcare Sector Average

Performance Comparison

DE:N040 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:N040	Nucana Plc	3.20	0.00	0.00%
XBIO	Xenetic Biosciences, Inc.	2.05	-1.07	-34.29%
IMRN	Immuron	0.88	-1.12	-56.00%
APRE	Aprea Therapeutics, Inc.	0.48	-0.92	-65.43%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Nucana AI Stock Analysis